3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
2
Myeloid
2
Thoracic
1
Other solid neoplasm
1
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Pancreatic Neoplasms
2
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Melanoma
1
Leukemia, Myeloid, Acute
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
COVID-19
1
Interventions
ruxolitinib
2
abiraterone
2
venetoclax
1
vactosertib
1
trametinib
1
rucaparib
1
regorafenib
1
ponatinib
1
pertuzumab
1
pembrolizumab
1
palbociclib
1
olaparib
1
neratinib
1
lorlatinib
1
lenvatinib
1
idelalisib
1
fludarabine phosphate
1
enzalutamide
1
entrectinib
1
enasidenib
1
durvalumab
1
dehydroftorafur
1
decitabine and cedazuridine drug combination
1
darolutamide
1
dacomitinib
1
dabrafenib
1
copanlisib
1
cobimetinib
1
cabozantinib
1
cabazitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Myelodysplastic Syndromes
×
bemcentinib
×
Gastrointestinal
×
Clear all
NCT06469138
2025-01-29
8479217
BerGenBio ASA
Phase 1
Completed
6 enrolled
17 charts